Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
|Articles|December 2, 2002
- Pharmaceutical Technology-12-02-2002
- Volume 26
- Issue 12
Fifth Annual International Employment Survey
Author(s)Maribel Rios
More than 1600 industry employees report about the status of their current work environment, including salary, job environment, and outlook for next year.
Advertisement
Articles in this issue
almost 24 years ago
Generic Drugs Take Center Stagealmost 24 years ago
Contract Servicesalmost 24 years ago
Determination by Analytical Sieving: Particle-Size Distribution, Part IIIAdvertisement
Related to this article
Germany is home to several prominent pharma companies and more than 1000 innovative biotechs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
2
Formulation Strategies for Next-Generation Multiagonists
3
First-in-Human Trial Speed: Why FDA Trails China
4
PharmTech AI Pulse Check: Why Pharma Should Weigh In on FDA's Generative AI Paper
5